Website profile

Biotechdispatch

biotechdispatch.com.au
All articles Clear site filter

Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t

  • 30articles · 30d
  • 13+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 97%with images
  • 336avg words
articles per day
Covers
People
Places
Organizations
Categories
  • Medical 23
  • Health & Wellness 20
  • Health 13
  • Economy, Business & Finance 11
  • Business & Industrial 6
  • Science & Technology 5
  • Finance & Business 4
  • News 4
Site tags

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


biotechdispatch.com.au > news > neurizon-therapeutics-appoints-chris-bremer-as-chief-executive-to-steer-als-drug-through-final-t

Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage

1+ week, 16+ hour ago   (504+ words) executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology...


biotechdispatch.com.au > news > dimerix-takes-control-of-us-development-pathway-for-new-kidney-injury-treatment

Dimerix takes control of US development pathway for new kidney injury treatment

3+ week, 6+ day ago   (311+ words) sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology...The Melbourne-based company said the transfer from UK biotechnology group Mission Therapeutics was complete...


biotechdispatch.com.au > news > avecho-resumes-pivotal-insomnia-trial-recruitment-after-positive-interim-review

Avecho resumes pivotal insomnia trial recruitment after positive interim review

2+ week, 14+ hour ago   (410+ words) Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a...


biotechdispatch.com.au > news > avecho-moves-to-deepen-global-partnering-push-as-cbd-insomnia-program-advances

Avecho moves to deepen global partnering push as CBD insomnia program advances - Biotech

2+ week, 6+ day ago   (418+ words) Avecho Biotechnology has appointed senior pharmaceutical executive Eve Williamson as a strategic business...


biotechdispatch.com.au > news > neuren-secures-european-approval-for-rett-syndrome-treatment

Neuren secures European approval for Rett syndrome treatment

2+ week, 6+ day ago   (354+ words) For the Melbourne-based biotechnology company, the decision represents both an important advance for...


biotechdispatch.com.au > news > us-health-agency-funds-broad-access-trial-for-melbourne-biotechs-als-drug

US health agency funds broad access trial for Melbourne biotech's ALS drug

5+ day, 11+ hour ago   (444+ words) with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology...

Web

External web results are waiting for the human check. Complete the press-and-hold control above. Google advertising and AI choices remain separate after verification.